Similar articles for PMID: 22818016

Year	Number of Results
1997	1
2000	1
2001	1
2002	1
2004	3
2005	9
2006	4
2007	3
2008	2
2009	5
2010	10
2011	13
2012	15
2013	12
2014	17
2015	6
2016	7
2017	11
2018	12
2019	9
2020	14
2021	15
2022	30
2023	11
2024	0

1

Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.

Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Liu LL, et al. Drugs. 2012 Jul 30;72(11):1521-33. doi: 10.2165/11635030-000000000-00000. Drugs. 2012. PMID: 22818016 Review.

2

Immunosuppressive treatment for proliferative lupus nephritis.

Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF. Tunnicliffe DJ, et al. Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. Cochrane Database Syst Rev. 2018. PMID: 29957821 Free PMC article. Review.

3

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.

Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Zhu B, et al. Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. doi: 10.1093/ndt/gfm066. Epub 2007 Apr 3. Nephrol Dial Transplant. 2007. PMID: 17405792 Review.

4

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.

Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Kamanamool N, et al. Medicine (Baltimore). 2010 Jul;89(4):227-235. doi: 10.1097/MD.0b013e3181e93d00. Medicine (Baltimore). 2010. PMID: 20616662 Free article. Review.

5

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Ginzler EM, et al. N Engl J Med. 2005 Nov 24;353(21):2219-28. doi: 10.1056/NEJMoa043731. N Engl J Med. 2005. PMID: 16306519 Free article. Clinical Trial.

6

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.

Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mak A, et al. Rheumatology (Oxford). 2009 Aug;48(8):944-52. doi: 10.1093/rheumatology/kep120. Epub 2009 Jun 3. Rheumatology (Oxford). 2009. PMID: 19494179

7

Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.

Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, Webster AC. Henderson LK, et al. Am J Kidney Dis. 2013 Jan;61(1):74-87. doi: 10.1053/j.ajkd.2012.08.041. Epub 2012 Nov 22. Am J Kidney Dis. 2013. PMID: 23182601

8

Treatment for lupus nephritis.

Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC. Henderson L, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235592 Updated. Review.

9

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.

Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Walsh M, et al. Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. doi: 10.2215/CJN.01200307. Epub 2007 Aug 8. Clin J Am Soc Nephrol. 2007. PMID: 17702723 Review.

10

Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.

Deng J, Luo L, Zhu L, Xie H, xie H. Deng J, et al. Turk J Med Sci. 2018 Oct 31;48(5):901-910. doi: 10.3906/sag-1804-57. Turk J Med Sci. 2018. PMID: 30384552 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

187 results

Results by year